Hedge funds and other notable investors have filed their 13Fs for the fourth quarter of 2012, disclosing many of their long equity positions as of the end of December. While the portfolios are from several weeks ago, there are still a few ways for investors to use this information. We have found, for example, that the most popular small cap stocks among hedge funds outperformed the market by 18 percentage points a year in our back tests (check out the details here). It can also be productive to treat individual 13Fs as “free” recommendations from fund managers. We have picked out the top five stock picks from Larry Robbins’s Glenview Capital, a mammoth fund that flies under the radar of the mainstream media.
Larry Robbins has operated Glenview since 2001. Before that, Robbins was a trader at Leon Cooperman’s Omega Advisors. Despite a poor performance in 2008, Glenview Capital recovered in 2010 by returning 15.7%, performing better than average hedge funds and the S&P 500 index. Overall, Robbins returned 301% after fees and expenses between January 2001 and December 2010. Robbins’s top holdings at the end of last year include health care companies, an insurance company and a multifaceted engineering firm. (See our recap from the previous quarter.)
Robbins’s top pick is Life Technologies Corp. (NASDAQ:LIFE). Life Technologies comprises 7.74% of Glenview Capital’s equity portfolio according to its most recent 13F filing with the SEC, and therefore represents a fairly concentrated position. The company is a global science operator, with divisions in research sciences, applied sciences and medical sciences. Life Technologies has a market cap of $10.52 billion, and a P/E ratio of 24.75. Revenue for 2012 was $3.8 billion, up 2% from 2011. The company’s share price is currently trading at $60.63, which is up over an impressive 25% year-to-date, but still off recent highs near $65 a pop. According to various rumors swirling their way around the blogosphere, Life appears to be acquisition target, which may be driving a majority of Mr. Market’s bullishness.
Robbins’s No. 2 stock pick is Tenet Healthcare Corp (NYSE:THC). Once again, Glenview Capital has a fairly large position in the company comprising 6.34% of its total equity portfolio—a total of nearly 14 million shares. Tenet Healthcare owns and operates acute care hospitals, ambulatory surgery centers, diagnostic imaging centers and related health care facilities. The company has a market cap of $4.2 billion, and a four-quarter trailing EPS of $1.36. The company recently reported increased revenue of $336 million for Q4 of 2012, up 16.7% from the previous quarter one year earlier.
Increased admissions to its facilities were a major force behind this boost, and Tenet has stated that expected FY2013 revenue should be between $1.325 billion and $1.425 billion. Tenet’s share price has skyrocketed more than 80% over the last six months, is up over 20% year-to-date, and is trading near a multi-year high of $40.29. Clearly Robbins has picked a winner with Tenet, and the growth picture looks intact moving forward.
American International Group Inc (NYSE:AIG), meanwhile, comes in at No. 3 in the hedgie’s equity portfolio, although he reduced his position by 3% last quarter.
American International Group Inc (NYSE:AIG) has seen its share price pop nearly 30% over the past year, and it still trades at a bargain bin price-to-book multiple of 0.59. More interestingly, AIG displaced Apple last quarter as the hedge fund industry’s top stock pick, and the leaner, meaner post-bailout insurer is quite the “growth at a reasonable price” play at the moment.
